Genomic profiling in low grade serous ovarian cancer: Identification of novel markers for disease diagnosis and therapy-Reference-Cited by-同舟云学术

Genomic profiling in low grade serous ovarian cancer: Identification of novel markers for disease diagnosis and therapy

Published:2022-11 Issue:2 Volume:167 Page:306-313
ISSN:0090-8258
Container-title:Gynecologic Oncology
language:en
Short-container-title:Gynecologic Oncology

Author:

ElNaggar Adam,Robins David,Baca Yasmine,Arguello David,Ulm Michael,Arend Rebecca,Mantia-Smaldone Gina,Chu Christina,Winer Ira,Holloway Rob,Krivak Tom,Jones Nathaniel,Galvan-Turner Valerie,Herzog Thomas J.,Brown Jubilee

Publisher

Elsevier BV

Subject

Obstetrics and Gynecology,Oncology

Reference46 articles.

1. Clinical behavior of stage II-IV low-grade serous carcinoma of the ovary;Gershenson;Obstet. Gynecol.,2006

2. Epithelial ovarian tumors of borderline malignancy;Rice;Gynecol. Oncol.,1990

3. Epidemiology of low-grade serous ovarian cancer;Plaxe;Am J Obstet Gynecol,2008

4. Low-grade serous primary peritoneal carcinoma;Schmeler;Gynecol. Oncol.,2011

5. Impact of age and primary disease site on outcome in women with low-grade serous carcinoma of the ovary or peritoneum: results of a large single-institution registry of a rare tumor;Gershenson;J. Clin. Oncol.,2015

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Molecular Surrogate Subtypes of Ovarian and Peritoneal Low-grade Serous Carcinoma;International Journal of Gynecological Pathology;2024-06-10

2. Identification of potentially actionable genetic variants in epithelial ovarian cancer: a retrospective cohort study;npj Precision Oncology;2024-03-22

3. Biology-driven therapy advances in high-grade serous ovarian cancer;Journal of Clinical Investigation;2024-01-02

4. First-in-human study of naporafenib (LXH254) with or without spartalizumab in adult patients with advanced solid tumors harboring MAPK signaling pathway alterations;European Journal of Cancer;2024-01

5. Survey of NF1 inactivation by surrogate immunohistochemistry in ovarian carcinomas;Gynecologic Oncology;2023-11